Zobrazeno 1 - 10
of 35
pro vyhledávání: '"J. C. Sadoff"'
Publikováno v:
Current Opinion in Immunology. 8:531-536
Preclinical DNA vaccine development has continued apace during the past year, with the investigation of several new infectious and non-infectious disease targets as well as advances in our understanding of some of the basic immunologic mechanisms, su
Autor:
J D Clements, D N Taylor, Joseph Shiloach, JohnB Robbins, A C Trofa, J C Sadoff, Dolores A. Bryla, Shousun C. Szu
Publikováno v:
Infection and Immunity. 62:4440-4444
To improve its immunogenicity for children and adults and to make it suitable for routine immunization of infants against typhoid fever, the capsular polysaccharide of Salmonella typhi (Vi) was bound to the B subunit of the heat-labile toxin (LT-B) o
Autor:
J C Beier, Gary W. Long, I Schneider, S.J. Cryz, D. M. Gordon, Louis Fries, J U Que, M Gross, J. C. Sadoff
Publikováno v:
Infection and Immunity. 60:1834-1839
Twenty-one malaria-naive volunteers were immunized with a vaccine consisting of a 22-kDa recombinant peptide (R32LR), derived from the repeat region of Plasmodium falciparum circumsporozoite (CS) protein, covalently coupled to detoxified Pseudomonas
Autor:
S M, Opal, C J, Fisher, J F, Dhainaut, J L, Vincent, R, Brase, S F, Lowry, J C, Sadoff, G J, Slotman, H, Levy, R A, Balk, M P, Shelly, J P, Pribble, J F, LaBrecque, J, Lookabaugh, H, Donovan, H, Dubin, R, Baughman, J, Norman, E, DeMaria, K, Matzel, E, Abraham, M, Seneff
Publikováno v:
Critical care medicine. 25(7)
To determine the therapeutic efficacy and safety of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in the treatment of patients with severe sepsis.Prospective, randomized, double-blind, placebo-controlled, multicenter trial with a pla
Publikováno v:
The Pediatric infectious disease journal. 16(6)
To assess the safety, tolerability and immunogenicity of COMVAX, a liquid, bivalent Haemophilus influenzae type b-hepatitis B vaccine, containing the polyribosylribitol phosphate (PRP)-Neisseria meningitidis outer membrane protein complex conjugate u
Autor:
C L, Sprung, L A, Eidelman, R, Pizov, C J, Fisher, E J, Ziegler, J C, Sadoff, R C, Straube, R V, McCloskey
Publikováno v:
Critical care medicine. 25(3)
To evaluate the timing of foregoing life-sustaining treatments in patients enrolled in a sepsis trial and to determine their influence on patient outcome and trial results.Subset of patients in a prospective, randomized, double-blind, placebo-control
Autor:
F, Nosten, C, Luxemburger, D E, Kyle, W R, Ballou, J, Wittes, E, Wah, T, Chongsuphajaisiddhi, D M, Gordon, N J, White, J C, Sadoff, D G, Heppner
Publikováno v:
Lancet (London, England). 348(9029)
Previous efficacy trials of SPf66 malaria vaccine have produced conflicting results in different populations. We report a randomised double-blind trial of the SPf66 vaccine conducted in Karen children aged 2-15 living in a malarious region of northwe
Autor:
C J, Fisher, J M, Agosti, S M, Opal, S F, Lowry, R A, Balk, J C, Sadoff, E, Abraham, R M, Schein, E, Benjamin
Publikováno v:
The New England journal of medicine. 334(26)
A recombinant, soluble fusion protein that is a dimer of an extracellular portion of the human tumor necrosis factor (TNF) receptor and the Fc portion of IgG1 (TNFR:Fc) binds and neutralizes TNF-alpha and prevents death in animal models of bacteremia
Autor:
C J, Fisher, S M, Opal, S F, Lowry, J C, Sadoff, J F, LaBrecque, H C, Donovan, J L, Lookabaugh, J, Lemke, J P, Pribble, S C, Stromatt
Publikováno v:
Circulatory shock. 44(1)
Clinical trials of anticytokines in sepsis have not been as straightforward as had been anticipated from results in animal models of sepsis and the role of cytokines in sepsis is now in question. Retrospective analysis of the results of a phase III t
Autor:
W A, Knaus, F E, Harrell, C J, Fisher, D P, Wagner, S M, Opal, J C, Sadoff, E A, Draper, C A, Walawander, K, Conboy, T H, Grasela
Publikováno v:
JAMA. 270(10)
To develop a survival model and severity assessment method to estimate the 28-day mortality risk for patients with sepsis syndrome entering phase 2 and 3 drug evaluations.Retrospective analysis of intensive care unit admissions with sepsis syndrome b